PARP1 and neoplasm: It becomes clear that BRCA1/2-dificient tumors exhibit high sensitivity and improved outcome to PARP inhibition based on results from these trials, as measured by standard radiographic criteria, 50% decrease in prostate-specific antigen (PSA), circulating tumor-cell counts, and progression-free survival or overall survival.